NVCT vs. NVO
NVCT (Nuvectis Pharma Inc) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — NVCT in Biotechnology, NVO in Drug Manufacturers - General. Over the past 3 years, NVCT returned 16.05%/yr vs -14.32%/yr for NVO. Their 0.08 correlation means their historical movements had little consistent relationship.
Performance
NVCT vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVCT achieves a 185.03% return, which is significantly higher than NVO's -4.23% return.
NVCT
- 1D
- -5.45%
- 1M
- 9.96%
- 6M
- 165.35%
- YTD
- 185.03%
- 1Y
- 216.47%
- 3Y*
- 16.05%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 45.94%
NVO
- 1D
- -8.78%
- 1M
- -6.64%
- 6M
- -18.01%
- YTD
- -4.23%
- 1Y
- 2.25%
- 3Y*
- -14.32%
- 5Y*
- 2.48%
- 10Y*
- 7.55%
- ALL TIME*
- 14.37%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $4.72M | $5.59M | $5.62M | |
| $504.41M | $480.49M | $577.88M |
NVCT vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
NVCT Nuvectis Pharma Inc | 185.03% | 39.56% | -35.13% | 11.20% | 89.87% |
NVO Novo Nordisk A/S | -4.23% | -39.22% | -15.93% | 54.84% | 31.30% |
Correlation
The correlation between NVCT and NVO is 0.17, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.17 |
Correlation (3Y) Balances recent behavior with more history. | 0.10 |
Correlation (All Time) Calculated using the full available price history since Feb 4, 2022 | 0.08 |
Fundamentals
NVCT:
$571.06M
NVO:
$209.19B
NVCT:
-$1.20
NVO:
DKK 27.42
NVCT:
35.43
NVO:
6.70
NVCT:
$0.00
NVO:
DKK 327.80B
NVCT:
$0.00
NVO:
DKK 268.30B
NVCT:
-$22.01M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVCT vs. NVO — Risk / Return Rank
NVCT
NVO
NVCT vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nuvectis Pharma Inc (NVCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCT | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.42 | ||
| Sortino ratioReturn per unit of downside risk | +2.47 | ||
| Omega ratioGain probability vs. loss probability | 1.44 | 1.06 | +0.37 |
| Calmar ratioReturn relative to maximum drawdown | 5.72 | 0.11 | +5.61 |
| Martin ratioReturn relative to average drawdown | 13.67 | 0.20 | +13.47 |
Loading charts...
Drawdowns
NVCT vs. NVO - Drawdown Comparison
The maximum NVCT drawdown since its inception was -77.89%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for NVCT and NVO.
Loading charts...
Drawdown Indicators
| NVCT | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.89% | -74.70% | -3.19% |
Max Drawdown (1Y)Largest decline over 1 year | -36.80% | -43.67% | +6.87% |
Max Drawdown (3Y)Largest decline over 3 years | -70.48% | -74.70% | +4.22% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -24.57% | -65.79% | +41.22% |
Average DrawdownAverage peak-to-trough decline | -52.49% | -17.93% | -34.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.38% | 23.97% | -8.59% |
Volatility
NVCT vs. NVO - Volatility Comparison
Nuvectis Pharma Inc (NVCT) has a higher volatility of 19.25% compared to Novo Nordisk A/S (NVO) at 12.28%. This indicates that NVCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVCT | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.25% | 12.28% | +6.97% |
Volatility (6M)Calculated over the trailing 6-month period | 73.03% | 36.87% | +36.16% |
Volatility (1Y)Calculated over the trailing 1-year period | 84.10% | 46.77% | +37.33% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 112.08% | 38.76% | +73.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 112.08% | 32.76% | +79.32% |
Dividends
NVCT vs. NVO - Dividend Comparison
NVCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.83%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVCT Nuvectis Pharma Inc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 3.83% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVCT vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Nuvectis Pharma Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NVCT and NVO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVCT has higher volatility (19.25%) compared to NVO (12.28%). In terms of maximum drawdown, NVCT dropped -77.89% vs NVO's -74.70%.
NVCT currently has the higher Sharpe Ratio (2.52 vs 0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVCT and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer